Roche’s Genentech has reported new data from the Phase III FENtrepid trial of fenebrutinib, an investigational Bruton’s tyrosine kinase inhibitor, for treating primary progressive multiple sclerosis ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results